As car­dio R&D shrinks in size, a new study high­lights some se­ri­ous pit­falls – and a pos­i­tive shift

In biotech cir­cles, it’s be­come an ar­ti­cle of faith that can­cer of­fers some of the best prospects in new drug de­vel­op­ment. Car­di­ol­o­gy, mean­while, looks like a long, ex­pen­sive and risky prospect. And a new study now un­der­scores the im­pact that shift in at­ti­tude has had, while spot­light­ing a solid­ly up­beat mi­gra­tion to a new gen­er­a­tion of ther­a­pies look­ing to carve out some nov­el re­sults as me-too drugs are rel­e­gat­ed to the side­lines. The au­thors, in­clud­ing Aaron Kessel­heim at Brigham and Women’s, al­so call out de­vel­op­ers for fail­ing to pub­lish the re­sults of failed stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER